AMENDMENTS TO EXISTING LICENSES ISSUED (continued):

<table>
<thead>
<tr>
<th>Location of Use/Possession of Material</th>
<th>Name of Licensed Entity</th>
<th>License Number</th>
<th>City of Licensed Entity</th>
<th>Amendment Number</th>
<th>Date of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Throughout TX</td>
<td>Proportional Technologies Inc.</td>
<td>L04747</td>
<td>Houston</td>
<td>33</td>
<td>11/10/17</td>
</tr>
<tr>
<td>Throughout TX</td>
<td>Sentinel Integrity Solutions Inc.</td>
<td>L06735</td>
<td>Houston</td>
<td>02</td>
<td>11/09/17</td>
</tr>
<tr>
<td>Throughout TX</td>
<td>American Piping Inspection Inc.</td>
<td>L06835</td>
<td>Kilgore</td>
<td>06</td>
<td>11/07/17</td>
</tr>
<tr>
<td>Throughout TX</td>
<td>Tri-Point Oil &amp; Gas Production Systems L.L.C.</td>
<td>L06897</td>
<td>Kountze</td>
<td>01</td>
<td>11/01/17</td>
</tr>
<tr>
<td>Throughout TX</td>
<td>Shared Medical Services Inc.</td>
<td>L06142</td>
<td>Nacogdoches</td>
<td>23</td>
<td>11/06/17</td>
</tr>
<tr>
<td>Throughout TX</td>
<td>Tracero</td>
<td>L03096</td>
<td>Pasadena</td>
<td>99</td>
<td>11/02/17</td>
</tr>
<tr>
<td>Throughout TX</td>
<td>Texas Oncology P.A.</td>
<td>L06759</td>
<td>San Antonio</td>
<td>05</td>
<td>11/06/17</td>
</tr>
<tr>
<td>Throughout TX</td>
<td>Hunter Industries Ltd.</td>
<td>L04175</td>
<td>San Marcos</td>
<td>12</td>
<td>11/13/17</td>
</tr>
</tbody>
</table>

RENEWAL OF LICENSES ISSUED:

<table>
<thead>
<tr>
<th>Location of Use/Possession of Material</th>
<th>Name of Licensed Entity</th>
<th>License Number</th>
<th>City of Licensed Entity</th>
<th>Amendment Number</th>
<th>Date of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austin</td>
<td>St. David's Healthcare Partnership L.P., L.L.P. dba St. David's North Austin Medical Center</td>
<td>L04910</td>
<td>Austin</td>
<td>102</td>
<td>11/14/17</td>
</tr>
<tr>
<td>Beaumont</td>
<td>The Goodyear Tire &amp; Rubber Company</td>
<td>L06063</td>
<td>Beaumont</td>
<td>05</td>
<td>11/13/17</td>
</tr>
<tr>
<td>Brenham</td>
<td>Scott &amp; White Hospital Brenham dba Baylor Scott &amp; White Medical Center - Brenham</td>
<td>L03419</td>
<td>Brenham</td>
<td>36</td>
<td>11/01/17</td>
</tr>
<tr>
<td>Crowley</td>
<td>Azztac Manufacturing Partnership Ltd. dba Azz Tubular Products</td>
<td>L06080</td>
<td>Crowley</td>
<td>02</td>
<td>11/14/17</td>
</tr>
<tr>
<td>Duncanville</td>
<td>Afridi Heart Care P.A.</td>
<td>L06005</td>
<td>Duncanville</td>
<td>14</td>
<td>11/14/17</td>
</tr>
<tr>
<td>Irving</td>
<td>Columbia Medical Center of Las Colinas Inc. dba Medical City Las Colinas</td>
<td>L05084</td>
<td>Irving</td>
<td>25</td>
<td>11/07/17</td>
</tr>
<tr>
<td>Pasadena</td>
<td>University Cancer Center of Huntsville/Brenham Inc.</td>
<td>L06070</td>
<td>Pasadena</td>
<td>09</td>
<td>11/13/17</td>
</tr>
<tr>
<td>Pharr</td>
<td>Harish Koolwal M.D., P.A.</td>
<td>L05149</td>
<td>Pharr</td>
<td>14</td>
<td>11/14/17</td>
</tr>
<tr>
<td>San Antonio</td>
<td>VHS San Antonio Imaging Partners L.P. dba Baptist M&amp;S Imaging Center</td>
<td>L04506</td>
<td>San Antonio</td>
<td>96</td>
<td>11/08/17</td>
</tr>
<tr>
<td>Throughout TX</td>
<td>Southern Services Inc. dba Southern Technical Services</td>
<td>L05270</td>
<td>Lake Jackson</td>
<td>63</td>
<td>11/14/17</td>
</tr>
<tr>
<td>Throughout TX</td>
<td>Techwell Surveys Corporation</td>
<td>L06089</td>
<td>Odessa</td>
<td>01</td>
<td>11/13/17</td>
</tr>
</tbody>
</table>

TERMINATIONS OF LICENSES ISSUED:

<table>
<thead>
<tr>
<th>Location of Use/Possession of Material</th>
<th>Name of Licensed Entity</th>
<th>License Number</th>
<th>City of Licensed Entity</th>
<th>Amendment Number</th>
<th>Date of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Longview</td>
<td>The Good Shepherd Hospital Inc. dba Christus Good Shepherd Medical Center - Longview</td>
<td>L02411</td>
<td>Longview</td>
<td>100</td>
<td>11/07/17</td>
</tr>
<tr>
<td>Lubbock</td>
<td>Covenant Health System dba Joe Arrington Cancer Center</td>
<td>L04881</td>
<td>Lubbock</td>
<td>70</td>
<td>11/14/17</td>
</tr>
<tr>
<td>San Antonio</td>
<td>Bakthavathsalam Athreya M.D., P.A. &amp; Associates</td>
<td>L06363</td>
<td>San Antonio</td>
<td>01</td>
<td>11/13/17</td>
</tr>
<tr>
<td>Throughout TX</td>
<td>IOS/PCI L.L.C.</td>
<td>L06790</td>
<td>Houston</td>
<td>03</td>
<td>11/09/17</td>
</tr>
</tbody>
</table>

TRD-201704982
Barbara L. Klein
Interim General Counsel
Department of State Health Services
Filed: December 6, 2017

Order Placing AB-CHMINACA, AB-PINACA and THJ-2201 into Schedule I

The Administrator of the Drug Enforcement Administration (DEA) issued a final rule placing N-(1-amino-3-methyl-1-oxobu-
stan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (Other names: "AB-CHMINACA"); N-(1-amino-3-methyl-1-oxobu-
stan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (Other names:

IN ADDITION December 15, 2017 42 TexReg 7197
"AB-PINACA"), and [1-(5-fluoropentyl)-1H-indazol-3-yl]naphthalen-1-yl)methanone (Other names: "THJ-2201") into Schedule I pursuant to the scheduling provisions of the of the United States Controlled Substances Act (CSA). The final rule was published in the Federal Register, Volume 82, Number 198, pages 47971-47974. This action was based on the following:

1. THJ-2201, AB-PINACA and AB-CHMINACA have a high potential for abuse that is comparable to other schedule I substances such as delta-9-tetrahydrocannabinol and JWH-018;
2. THJ-2201, AB-PINACA and AB-CHMINACA have no currently accepted medical use in treatment in the United States; and
3. There is a lack of accepted safety for use of THJ-2201, AB-PINACA and AB-CHMINACA under medical supervision.

Pursuant to Section 481.034(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Health and Safety Code, Chapter 481, at least thirty-one days have expired since notice of the above referenced actions were published in the Federal Register. In the capacity as the Commissioner of the Texas Department of State Health Services, John Hellerstedt, M.D., does hereby order that the substances THJ-2201, AB-PINACA and AB-CHMINACA be placed into Schedule I.

SCHEDULES

Nomenclature: Controlled substances listed in these schedules are included by whatever official, common, usual, chemical, or trade name they may be designated.

SCHEDULE I

I Hallucinogenic substances

Unless specifically excepted or unless listed in another schedule, a material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances or that contains any of the substance's salts, isomers, and salts of isomers if the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation (for the purposes of this Schedule I hallucinogenic substances section only, the term "isomer" includes optical, position, and geometric isomers):

* (70) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-[(cyclohexylmethyl)-1H-indazol-3-carboxamide (Other names: "AB-CHMINACA");
* (71) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazol-3-carboxamide (Other names: "AB-PINACA"); and
* (72) [1-(5-fluoropentyl)-1H-indazol-3-yl]naphthalen-1-yl)methanone (Other names: "THJ-2201").

Changes are denoted by an asterisk *

TRD-201704861
Barbara L. Klein
Interim General Counsel
Department of State Health Services
Filed: December 6, 2017

Order Temporarily Adding Ortho-Fluorofentanyl, Tetrahydrofuranyl Fentanyl, Methoxyacetyl Fentanyl and FUB-AMB into Schedule I

The Administrator of the Drug Enforcement Administration issued a temporary scheduling order to schedule the synthetic opioids N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propanamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other names: "ortho-fluorofentanyl, 2-fluorofentanyl"); N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuranyl-2-carboxamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other name: "tetrahydrofuranylfentanyl"), and 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other name: "methoxyacetyl fentanyl") into Schedule I of the Controlled Substances Act effective October 26, 2017. This temporary scheduling order was published in the October 26, 2017 issue of the Federal Register, Volume 82, Number 206, pages 49504-49508. The Administrator has taken action based on the following:

1. Ortho-fluorofentanyl, tetrahydrofuranyl fentanyl, and methoxyacetyl fentanyl have a high potential for abuse.
2. Ortho-fluorofentanyl, tetrahydrofuranyl fentanyl, and methoxyacetyl fentanyl have no current accepted medical use in treatment in the United States.
3. There is a lack of accepted safety for use under medical supervision for ortho-fluorofentanyl, tetrahydrofuranyl fentanyl, and methoxyacetyl fentanyl.
4. Control of ortho-fluorofentanyl, tetrahydrofuranyl fentanyl, and methoxyacetyl fentanyl is necessary to avoid an imminent hazard to the public safety.

The Administrator of the Drug Enforcement Administration issued a temporary scheduling order to schedule the synthetic cannabinoids 2-{[1-(4-fluorobenzyl)-1H-indazole-3-carboxamido]-3-methylbutanoate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: "FUB-AMB, MMB-FUBINACA, AMB-FUBINACA") into Schedule I of the Controlled Substances Act effective November 3, 2017. This temporary scheduling order was published in the November 3, 2017 issue of the Federal Register, Volume 82, Number 212, pages 51154-51158. The Administrator has taken action based on the following:

1. FUB-AMB has a high potential for abuse.
2. FUB-AMB has no current accepted medical use in treatment in the United States.
3. There is a lack of accepted safety for use under medical supervision for FUB-AMB.
4. Control of FUB-AMB is necessary to avoid an imminent hazard to the public safety.

Pursuant to Section 481.034(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Health and Safety Code, Chapter 481, at least thirty-one days have expired since notice of the above referenced actions were published in the Federal Register. In the capacity as the Commissioner of the Texas Department of State Health Services, John Hellerstedt, M.D., does hereby order that the substances ortho-fluorofentanyl, tetrahydrofuranyl fentanyl, methoxyacetyl fentanyl, and FUB-AMB be placed into Schedule I temporarily listed substances.

SCHEDULE I

--Schedule I temporarily listed substances subject to emergency scheduling by the United States Drug Enforcement Administration.

Unless specifically excepted or unless listed in another schedule, a material, compound, mixture, or preparation that contains any quantity of the following substances or that contains any of the substance's salts, esters, ethers, isomers, optical isomers, positional isomers, geometric isomers and salts of isomers, esters, and ethers if the existence of the salts, isomers, esters, ethers and salts of isomers, esters and ethers is possible within the specific chemical designation.
14. N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (Other names: "ortho-fluorofentanyl, 2-fluorofentanyl");
15. N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide (Other name: "tetrahydrofuran yl fentanyl");
16. 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other name: "methoxyacetethyl fentanyl"); and
17. methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (Other names: "FUB-AMB, MNB-FUBINACA, AMB-FUBINACA").

Changes to the schedules are marked with an asterisk.

TRD-201704680
Barbara L. Klein
Interim General Counsel
Department of State Health Services
Filed: December 6, 2017

University of Houston System
Business and Service Review of Pouring Rights

The University of Houston System announces a Request for Proposal (RFP) for consultant services pursuant to Government Code, Chapter 2254, Subchapter B.

RFP781-18005, Business and Service Review of Pouring Rights Contract

Purpose:
The University of Houston System (UHS) Auxiliary Services is seeking competitive responses to a Request for Proposal ("RFP") for a Consultant to provide an independent analysis of its pouring rights and beverage vending contract that incorporates industry best practices and creative solutions that will meet the System's complex needs.

Eligible Applicants:
Consulting firms with related knowledge and experience in:
Firms that have expertise with evaluating pouring rights and beverage vending contracts.

Services to be performed:
* an independent, comprehensive evaluation of the System pouring rights and beverage vending contract
* guidance and assistance in any potential service and technology enhancements related to the pouring rights and beverage contract management
* guidance to the System regarding the business operations of this contract, including a review of contract oversight, such as commission reconciliations, accounting practices, and contract management related to current terms in the agreement
* development of a comprehensive five year business plan and proposal for the business operation of the pouring rights contract development of performance indicators that can be used to monitor contract performance from a university perspective and be easily incorporated into our contract management software
* guidance for management policies, procedures, and systems, including support in the event of a potential re-bidding of the System pouring rights and beverage vending contract recommendations to the System including advice to future contract length and terms, as well as financial and operational advice related to this agreement and its oversight.

Finding by Chief Executive Officer, Renu Khator:
After reviewing the current status and discussing this matter with the staff, the evaluation of these services can only be conducted by a firm considered expert in pouring rights and beverage vending contracts. The University believes that using a third-party consultant, who has conducted similar evaluations for universities similar in context and size to universities within the UH System, will provide the System with best practices that can be used to improve the service to our customers. The expertise needed for this evaluation is complex and requires a comprehensive knowledge of national industry trends related to pouring rights agreements. Currently, the Auxiliary Services staff does not have the expertise to complete this evaluation. Thus, it is necessary for the System to engage a consultant to advise it regarding its pouring rights contract and management of this contract, and make recommendations, as appropriate for the improvement of this program.

Review and Award Criteria:
All proposals will be evaluated by appointed representatives of the University in accordance with the following procedures:
Purchasing will receive and review each RFP proposal to ensure it meets the requirements of the RFP. Qualified proposals will be given to the selection committee.
Each member of the selection committee will independently evaluate the qualified proposals according to the criteria in section IX of the RFP, except for price, and send their evaluations to Purchasing. Price will be evaluated by Project Manager.
Purchasing will combine the committee's scores to determine which proposal received the highest combined score.
Purchasing will notify the respondent with the highest score that the University intends to contract with them.
Deadlines: UH must receive proposals according to instructions in the RFP package on or before Tuesday, January 16, 2018, at 2:00 p.m. CDT and the UHB Subcontracting Plan (HSP) on or before Wednesday, January 17, 2018, at 2:00 p.m. CDT.
Obtaining a copy of the RFP: Copies will be available on the Electronic State Business Daily (ESBD) at http://www.txsmartbuy.com/sp.
The sole point of contact for inquiries concerning RFP is:
Jack Tenner
UH Purchasing
5000 Gulf Freeway, ERP 1, Rm 204
Houston, Texas 77204-5015
Phone: (713) 743-5671
Email: jttenner@central.uh.edu
TRD-201704875
Jackie D. Tenner
Director of Purchasing
University of Houston System
Filed: December 1, 2017

Texas Department of Insurance
Company Licensing

IN ADDITION December 15, 2017 42 TexReg 7199